Clinical Trial Update: Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating biomarkers and response to natalizumab in multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED